Cambridge University Press
  • Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • The
    Prescriber's Guide
  • Essential
    Psychopharmacology
  • Essential
    Neuropharmacology
  • Other
    Resources
    • Next Generation Antidepressants:
      Beyer and Stahl
  • Stahl's
    Illustrated
  • Drug
    Interaction
 
  • My Bookmarks
  • TOC
  • Pizotifen
  • Therapeutics
  • Side Effects
  • Dosing and Use
  • Special Populations
  • Art of Psychopharmacology
  • Suggested Reading

Pizotifen

Therapeutics

Brands

• Sanomigran

Generic?

Yes

Class

• Antihistamine

Commonly Prescribed for

(FDA approved in bold)
• Migraine prophylaxis (children and adults)
• Cluster headache prophylaxis
• Treatment of serotonin syndrome
• Anxiety/social phobia

How the Drug Works

• An antihistamine and 5-HT2 receptor antagonist that is structurally related to tricyclic antidepressants. Has weak anticholinergic effects and may act as a calcium channel blocker at high doses. The relative importance of each action in headache prophylaxis is unclear. Prevention of cortical spreading depression may be the mechanism of action for all migraine preventatives

How Long Until It Works

• Migraines may decrease in as little as 2 weeks, but can take up to 2 months to see full effect

If It Works

• Migraine - goal is a 50% or greater decrease in migraine frequency or severity. Consider tapering or stopping if headaches remit for more than 6 months or if considering pregnancy

If It Doesn't Work

• Increase to highest tolerated dose
• Migraine: address other issues, such as medication-overuse, other coexisting medical disorders, such as anxiety, and consider changing to another agent or adding a second agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Migraine: For some patients with migraine, low-dose polytherapy with 2 or more drugs may be better tolerated and more effective than high-dose monotherapy. May use in combination with AEDs, antidepressants, natural products, and non-medication treatments, such as biofeedback, to improve headache control

Tests

• Monitor weight during treatment
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$261
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us